BioCryst Pharmaceuticals | BCRX - Selling And Administration Expenses


BioCryst Pharmaceuticals reported $95.78M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Chugai Pharma JPY 36.93B 9.04B Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025